Already a member? Login to access this report free.
Report Highlights
The global market for diabetes therapeutics and diagnostics is estimated to increase from $102.2 billion in 2023 to reach $132.0 billion by 2028, at a compound annual growth rate (CAGR) of 5.2% from 2023 through 2028.
Report Includes
- 162 data tables and 63 additional tables
- An up-to-date overview and analysis of the global markets for diabetes therapeutics and diagnostics
- Analyses of the global market trends, with market revenue (sales figures) for 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
- Understanding of the upcoming market potential for AI in diabetic mellitus management with an emphasis on new products and solutions/platform technologies, and areas of focus to forecast this market into various segments and sub-segments
- Estimation of the actual market size and revenue forecast for the global diabetes therapeutics and diagnostics market, and corresponding market share analysis based on product type, end user, and geographical region
- In-depth information (facts and figures) on major market dynamics, opportunities and gaps estimating the demand, technology adaptations in diabetes care, industry developments, regulatory dynamics, and the COVID-19 impact on the progress of this market
- Identification of the companies best positioned to meet this demand owing to or in conjunction with their proprietary technologies, product launches, and other strategic advantages
- Review of key patent grants and patent applications on diabetes therapeutics and diagnostics, and emerging technologies and new developments in this market
- Analysis of the company competitive landscape based on their recent developments, financial performance, segmental revenues, and operational integration
- Company profiles of the leading global players, including Novo Nordisk, Sanofi S.A., Lilly, Takeda, Danaher Corp., and AstraZeneca
Report Scope
This report discusses the implications of the trends mentioned above in the context of the current size and growth of the diabetes market, in global terms and by the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on M&A activity. Five-year global sales forecasts are provided for the leading drug and device categories, and there are country-level breakdowns of the diabetes market.
Major players, competitive intelligence, innovative technologies, market dynamics and regional opportunities are discussed in detail. The report examines recent developments and product portfolios of major players. The patent analysis focuses on technological trends in recent years in regions such as the U.S., Europe, and Japan. The report presents a market analysis and estimates the compound annual growth rate (CAGR) for the diabetes therapeutics and diagnostics market.
This report segments the global market by these geographic regions: North America, Europe, Asia-Pacific and the Rest of the World. For market estimates, data is provided for 2022 as the base year, 2023 and forecast through year-end 2028.
Report Synopsis
| Report Metrics | Details | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Base year considered | 2022 | ||||||||||||||||||||||||||||||
| Forecast period considered | 2023-2028 | ||||||||||||||||||||||||||||||
| Base year market size | $97.3 billion | ||||||||||||||||||||||||||||||
| Market size forecast | $132.0 billion | ||||||||||||||||||||||||||||||
| Growth rate | CAGR of 5.2% for the forecast period of 2023-2028 | ||||||||||||||||||||||||||||||
| Units considered | $ Millions | ||||||||||||||||||||||||||||||
| Segments covered | Product Group, End-User, and Region | ||||||||||||||||||||||||||||||
| Regions covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW). | ||||||||||||||||||||||||||||||
| Countries covered | U.S., Canada, Mexico, France, Germany, U.K., Italy, Spain, China, India, and Japan | ||||||||||||||||||||||||||||||
| Key Market Drivers |
|
||||||||||||||||||||||||||||||
| Companies studied |
|
Frequently Asked Questions (FAQs)
Analyst Credentials
Bejini Sandeep Kumar– Assistant Manager - Life Sciences Research
Sandeep Kumar has over 11 years of experience in pharmaceutical and medical equipment research and consulting. With expertise lying in business research studies, such as industry analysis, strategic and financial analysis, opportunity assessment and competitor intelligence. Sandeep has extensive experience in market research and analysis, specializing in healthcare, medical devices, biotechnology, healthcare IT, pharmaceuticals, and others. He holds a bachelor’s degree in Biotechnology and a Post Graduate degree in Business Management from Liverpool John Moores University (LJMU).
Related Reports
Global Diabetic Care Devices Market
The global market for diabetes monitoring devices is expected to grow from $16.6 billion in 2024 to $26.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.1% from 2024 through 2029.
Point-of-Care Diagnostics: Technologies and Global Markets
The global market for point-of-care diagnostics was valued at $36.9 billion in 2023. It is expected to grow from $40.6 billion in 2024 to $65.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.2% from 2024 through 2029.
Infusion Pumps and Devices: Technologies and Global Markets
The global market for infusion pumps is expected to grow from $10.1 billion in 2024 and is projected to reach $14.7 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.7% during the forecast period of 2024 to 2029.
Global Markets for Generic Drugs
The global market for generic drugs is expected to grow from $435.3 billion in 2023 and projected to reach $655.8 billion by the end of 2028, at a compound annual growth rate (CAGR) of 8.5% from 2023 to 2028.
Track the Latest Global Tariff Developments
In today's fast-paced global economy, tariffs are no longer static—they are dynamic levers shaped by geopolitical realignments, supply chain vulnerabilities, inflationary pressures, and sustainability-driven trade reforms. As governments worldwide recalibrate their trade strategies, businesses are left to navigate a maze of shifting rules, rising costs, and regulatory uncertainty.
Our analysis empowers you with real-time updates and in-depth expert analysis on all facets of global tariff activity. From new trade agreements and sanctions to abrupt tariff hikes and retaliatory duties, we monitor developments across borders, sectors, and industries—so you don't have to.
Whether it's the ongoing U.S.–China trade dynamics, the evolving EU Carbon Border Adjustment Mechanism (CBAM), or the emerging policies in India, ASEAN, and Latin America, we provide full-spectrum coverage. We also track multilateral trade negotiations, World Trade Organization (WTO) rulings, and sector-specific duty structures—ensuring you are always ahead of global trade shifts.
With our analysis, you can stay informed, identify risks, and confidently respond to tariff changes—no matter where you operate.
Ready to see what tariff means for your business?
Consult with our experts or request your custom Tariff Impact Brife today
Stay Informed, Stay Competitive
In today's interconnected and unpredictable global economy, staying ahead of tariff shifts is not just important—it's essential. BCC Research provides decision-makers with trusted, research-driven insights that turn uncertainty into opportunity.
Our in-depth market analysis and trade intelligence help you decode how tariff changes impact your specific sector—manufacturing, healthcare, technology, agriculture, or energy. We break down complex data into actionable knowledge through comprehensive reports, expert commentaries, and sector-focused forecasts.
Our analysis includes:
- Thorough breakdowns of current and proposed tariff policies and how they affect regional and global trade flows.
- Sector-specific implications, helping you understand the strategic impact on sourcing, pricing, and competitiveness.
- Forward-looking insights to support risk management, planning, and response strategies for evolving trade conditions.
With BCC Research, you gain more than just information—you gain clarity and confidence to make well-informed decisions in a volatile trade environment.
Don't let tariffs catch you off guard—let our insights guide your strategy.
Recent Reports
Thermo Fisher Scientific Inc.: 360° Company Analysis
This report provides a comprehensive analysis of Thermo Fisher Scientific Inc., covering key details such as key milestones/history, product offerings, technologies, major applications and end-user industries it serves.
Needle-Free Devices: Technologies and Global Markets
The global market for needle-free devices was valued at $15.5 billion in 2024 and is estimated to increase from $17.0 billion in 2025 to reach $27.7 billion by 2030, at a compound annual growth rate (CAGR) of 10.2% from 2025 through 2030.
Koninklijke Philips N.V.: 360° Company Analysis
The report discusses a 360° analysis of Koninklijke Philips N.V. It covers various aspects of Koninklijke Philips N.V., including products, business segments, history, distributors, and financial and strategic development.
Global Thyroid Gland Disorders: Diagnostics and Treatment Market
The global market for diagnostics and treatment of thyroid gland disorders was valued at $15.5 billion in 2024 and is estimated to increase from $16.3 billion in 2025 to reach $21.0 billion by 2030, at a compound annual growth rate (CAGR) of 5.2% from 2025 through 2030.
Global Outpatient Clinics Market
The global outpatient clinics market is expected to grow from $4.4 trillion in 2024 and is projected to reach $6.3 trillion by the end of 2029, at a compound annual growth rate (CAGR) of 7.6% during the forecast period of 2024 to 2029.
Top Trending Reports
Next-Generation Advanced Batteries: Global Markets
The global market for next-generation advanced batteries is estimated to grow from $1.5 billion in 2024 to reach $5.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 28.5% from 2024 through 2029.
Global Pharmaceutical Drugs Industry: Competitive Landscape 2023
This report discusses the global pharmaceutical drugs industry and its competitive landscape in terms of significant player market ranking and top pharmaceutical drugs. Company profiles of the top 50 pharmaceutical companies, innovative products and technologies, trends and market dynamics, competitive intelligence, and regional trends are well-researched and analyzed in this report.
Global Markets and Manufacturing Technologies for Protein Drugs
The global protein drugs market is expected to grow from $441.7 billion in 2024 and is projected to reach $655.7 billion by the end of 2029, at a compound annual growth rate (CAGR) of 8.2% during the forecast period of 2024 to 2029.
Biologic Therapeutic Drugs: Technologies and Global Markets
The global market for biologic therapeutic drugs is estimated to increase from $499.2 billion in 2024 to reach $794.5 billion by 2029, at a compound annual growth rate (CAGR) of 9.7% from 2024 through 2029.
Global Markets for Emerging Medical Device Technologies
The global market for emerging medical devices is estimated to increase from $136.6 billion in 2024 to reach $223.9 billion by 2029, at a compound annual growth rate (CAGR) of 10.4% from 2024 through 2029.
Report Highlights
The global diabetes market should reach $155 billion by 2021 from $125 billion in 2016 at a compound annual growth rate (CAGR) of 4.4%, from 2016 to 2021.
Report Includes
- An overview of the global market for diabetes
- Analyses of global market trends, with data from 2015, estimates for 2016, and projections of CAGRs through 2021.
- Analysis of the devices and instruments used in the diagnosis and monitoring of diabetes
- A close look at major forces contributing to the vigorous growth of the diabetes market
- Evaluation of other factors influencing the market such as health care policies, demographics, and the wider economic environment
- Discussion covering companies in the relevant pharmaceutical and medical industries through company profiles of many leading players in the field
Report Highlights
The global market for diabetes therapeutics and diagnostics was valued at $110 billion in 2011 and should reach nearly $118.7 billion in 2012. Total market value is expected to reach nearly $157 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 5.7%.
Report Highlights
-
The global market for therapeutic and diagnostic products for diabetes is valued at $38 billion in 2010. This market is expected to grow at a compound annual growth rate (CAGR) of 6.1% to reach $51.2 billion in 2015.
-
Insulin products, including administration devices, are worth an estimated $16.4 billion in 2010. This sector is expected to reach $22 billion in 2015, a 6.1% compound annual growth rate (CAGR).
-
Oral hypoglycemic drugs are expected to achieve the highestcompound annual growth rate (CAGR) of 8%, increasing from $10.3 billion in 2010 to $15.1 billion in 2015.
Report Highlights
- The global market for diabetes therapeutics and diagnostics increased from $208.5 billion in 2007 to an estimated $213.8 billion by the end of 2008. It should reach $241.9 billion by 2013, a compound annual growth rate (CAGR) of 2.5%.
- The global diabetes market will become one of the largest healthcare markets over the next five years, due in large part to the epidemic explosion of the type II diabetes population.
- Over the next five years, market leaders will overcome technology barriers to bring non-invasive, insulin-dependent products to the market.
Report Highlights
-
The total market for diabetes drugs and devices is estimated at $18 billion in 2002. Growing at an average annual rate (AAGR) of 11.5%, the market is expected to exceed $30.7 billion in 2007.
-
Drug sales in 2002 are expected to be $12.5 billion, increasing to almost $21 billion by 2007 at an AAGR of 10.3%.
-
Insulin was 33% of the market in 2000 and is expected to hold on to that share.
-
Sulfanylureas and biguanides are expected to lose considerable market share to generics, newer classes of drugs, and to the extremely popular thiazolidinediones.
-
The two major diabetes medical devices are glucose monitors and insulin pumps. Glucose monitors are expected to rise at an AAGR of 13.7% to $8 billion by 2007. Insulin pumps are expected to grow to $1.8 billion by 2007 at an AAGR of 18.7%.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More